Original Investigation
Incident Myocardial Infarction and Very Late Stent Thrombosis in Outpatients With Stable Coronary Artery Disease

https://doi.org/10.1016/j.jacc.2017.02.050Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

Current data are lacking for incidence, correlates, and prognosis associated with incident myocardial infarction (MI) in patients with stable coronary artery disease (CAD). Furthermore, the contribution of very late stent thrombosis (VLST) to these events remains poorly understood.

Objectives

This study aimed to analyze the residual risk of MI, together with relevant associated factors, and related mortality in stable CAD outpatients.

Methods

The multicenter CORONOR (Suivi d’une cohorte de patients COROnariens stables en region NORd-Pas-de-Calais) study enrolled 4,184 unselected outpatients with stable CAD (i.e., MI or coronary revascularization >1 year previously). Five-year follow-up was achieved for 4,094 patients (98%).

Results

We identified a linear risk of incident MI (0.8% annually), with ST-segment elevation MI constituting one-third of all cases. Current smoking, low-density lipoprotein cholesterol, multivessel CAD, diabetes with glycosylated hemoglobin >7%, and persistent angina were all associated with increased risk, and prior bypass surgery was associated with decreased risk. When used as a time-dependent variable, incident MI was associated with an increased risk of death (hazard ratio: 2.05; p < 0.0001). Among patients with prior stent implantation, VLST was causal in 20% of MI cases and presented more often as ST-segment elevation MI versus MI not related to a stented site (59% vs. 26%, p = 0.001). Adjusted mortality was 4 times higher in patients with VLST than in MI not related to a stented site.

Conclusions

In stable CAD outpatients, incident MI occurs at a stable rate of 0.8% annually, is related to VLST in one-fifth of cases, and is associated with an increased mortality risk, especially for VLST. Multivessel CAD and residual uncontrolled risk factors are strongly associated with MI.

Key Words

coronary artery disease
myocardial infarction
percutaneous coronary intervention
secondary prevention
stent thrombosis

Abbreviations and Acronyms

BMS
bare-metal stent
CAD
coronary artery disease
DES
drug-eluting stent
LDL
low-density lipoprotein
MI
myocardial infarction
NSTEMI
non–ST-segment elevation myocardial infarction
PCI
percutaneous coronary intervention
STEMI
ST-segment elevation myocardial infarction
VLST
very late stent thrombosis

Cited by (0)

This study was supported by the Fédération Française de Cardiologie, Paris, France. Dr. Lemesle has received fees for lectures or consulting from AstraZeneca, Bayer, Biopharma, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, MSD/Schering-Plough, Pfizer, Sanofi, Servier, and The Medicines Company. Dr. Lamblin has received a research grant from Pfizer; and fees for lectures or consulting from Actelion, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, MSD/Schering-Plough, Novartis, Pfizer, Sanofi, and Servier. Dr. Bauters has received travel grants from MSD/Schering-Plough, Boehringer Ingelheim, and Servier. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.